Iovance Biotherapeutics Posts Record Revenue on Amtagvi Demand — Iovance Biotherapeutics, Inc.

Event summary

Iovance Biotherapeutics reported record Q2 2026 revenue of $99.3M, up 66% YoY.
U.S. Amtagvi revenue reached ~$91M, driving a 56% gross margin.
FDA granted Fast Track Designation for lifileucel in soft tissue sarcomas.
Global expansion continues with approvals in Australia and pending reviews in the UK and Switzerland.

The big picture

Iovance Biotherapeutics' record Q2 revenue highlights the growing demand for its Amtagvi therapy, particularly in the U.S. The company's strategic focus on expanding into new indications and global markets positions it to capitalize on the increasing adoption of TIL therapies. With a strong clinical pipeline and ongoing cost efficiencies, Iovance is poised to accelerate progress toward profitability.

What we're watching

Revenue Guidance Update: Whether Iovance's strong Q2 performance will lead to an upward revision of its FY26 revenue guidance.
Clinical Pipeline Progress: The pace at which lifileucel advances across new solid tumor indications, particularly in NSCLC and soft tissue sarcomas.
Global Expansion Strategy: How successful Iovance will be in securing approvals and reimbursement for Amtagvi in key international markets like the UK and Switzerland.